Finzati - Logo
AMGN logo

Amgen Inc.

AMGN • Drug Manufacturers - General
$437.23
▼ -6.89 (-1.55%)
Current price
EarningsLatest report: Jun 30, 2026
FAVORABLE PROFILEAttractiveConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Strong business quality with supportive growth and cash-flow evidence. Valuation still matters, but the historical ratio profile is favorable.
Market Cap
$237.85B
Growth
20.7%
Cash Flow
5/5
Trend
Stable
Evidence
Stable or improving margins · 21.0%Positive revenue growth · 10.6%Positive free cash flow · 15.06Consistent free cash flow · 5/5High debt level · 6.31
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 12:06 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$437.23
Change-1.55%
Shares Out544.00M
Market Cap$237.85B
Enterprise Value$281.17B
52W Range269.77 - 418.40
Beta0.40
P/E27.20
P/S6.24
P/B20.35
P/FCF23.38
EV/Sales7.37

Investment DNA

How strong this company looks for long-term investors

74
out of 100
Business Quality
Margins, moat, returns
85/100
Financial Strength
Debt, cash, stability
44/100
Growth Potential
Revenue and expansion
67/100
Price Attractiveness
Cheap or expensive today
56/100
Why this score▼
Stable or improving margins · 21.0%Positive revenue growth · 10.6%Positive free cash flow · 15.06Consistent free cash flow · 5/5High debt level · 6.31

Analyst view

Analyst sentiment and price target

AMGN
Analyst sentiment
Based on 40 analyst votes · 2026-09-05
75/100
Bullish
Bullish
23
Hold
14
Bearish
3
Price Target
2026-08-07
Low
$230.00
Mean
$371.61
Median
$367.50
High
$450.00

Company Overview

IPO: 6/17/1983
Industry: Drug Manufacturers - General
P/B i: 20.35
Debt / Equity i: 6.31
Operating Margin: 29.06%
Net Margin: 20.99%
ROE i: -
ROIC: -

Financial Health

Score9 / 20
Debt / Equity: 6.31
Current Ratio: 1.14
Quick Ratio: 0.90
Status: Moderate

Warnings

  • High debt level

Insider Transactions

Recent executive and insider activity

Austin Wanda M
Transaction: 05/19/2026
BUY
Change
+665
Price
Not reported
Filing
05/21/2026
Type
BUY
Drake Michael V
Transaction: 05/19/2026
BUY
Change
+665
Price
Not reported
Filing
05/21/2026
Type
BUY
Druker Brian
Transaction: 05/19/2026
BUY
Change
+665
Price
Not reported
Filing
05/21/2026
Type
BUY